Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Baseline azithromycin resistance in the gut microbiota of preterm-born infants stool

ABSTRACT: Azithromycin resistance STOOL

PROVIDER: PRJEB61860 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR11347200_1.fastq.gz	Fastqsanger.gz
	ERR11347200_2.fastq.gz	Fastqsanger.gz
	ERR11347201_1.fastq.gz	Fastqsanger.gz
	ERR11347201_2.fastq.gz	Fastqsanger.gz
	ERR11347202_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 218

Similar Datasets

Baseline azithromycin resistance in the gut microbiota of preterm-born infants

Project description:Azithromycin resistance BAL

| PRJEB61857 | ENA

Baseline azithromycin resistance in the gut microbiota of preterm born infants.

Project description:BackgroundMacrolides, including azithromycin, are increasingly used in preterm-born infants to treat Ureaplasma infections. The baseline carriage of macrolide resistance genes in the preterm stool microbiota is unknown.ObjectivesIdentify carriage of azithromycin resistant bacteria and the incidence of macrolide resistant genes.MethodsAzithromycin resistant bacteria were isolated from serial stool samples obtained from preterm infants (≤32 weeks' gestation) by culturing aerobically/anaerobically, in the presence/absence of azithromycin. Using quantitative PCR, we targeted 6 common macrolide resistance genes (erm(A), erm(B), erm(C), erm(F), mef(A/E), msr(A)) in DNA extracted from selected bacteria resistant to azithromycin.ResultsFrom 89 stool samples from 37 preterm-born infants, 93.3% showed bacterial growth in aerobic or anaerobic conditions. From the 280 azithromycin resistant isolates that were identified, Staphylococcus (75%) and Enterococcus (15%) species dominated. Macrolide resistance genes were identified in 91% of resistant isolates: commonest were erm(C) (46% of isolates) and msr(A) (40%). Multiple macrolide resistance genes were identified in 18% of isolates.ConclusionMacrolide resistance is common in the gut microbiota of preterm-born infants early in life, most likely acquired from exposure to the maternal microbiota. It will be important to assess modulation of macrolide resistance, if macrolide treatment becomes routine in the management of preterm infants.Impact statementAzithromycin resistance is present in the stool microbiota in the first month of life in preterm infants 91% of azithromycin resistant bacteria carried at least one of 6 common macrolide resistant genes Increasing use of macrolides in the preterm population makes this an important area of study.

| S-EPMC10798878 | biostudies-literature

Metaproteomics on preterm infant stool

Project description:Development of the gut microbiota is greatly impacted in preterm infants. Despite increasing knowledge about microbiota composition in preterm infants, knowledge about the functional signatures of the intestinal microbiota remains limited. The aim was to study transitions in microbiota activity during the first six postnatal weeks in ten preterm infants. A total of 64 stool samples were measured by LC-MS/MS.

2017-07-14 | PXD005574 | Pride

Stool microbiota stability

Project description:Stool microbiota stability

| PRJEB79382 | ENA

Comparison of Azithromycin treated and non-treated human lung fibroblasts

Project description:Azithromycin has been shown to have anti-fibrotic effects on idiopathic lung fibroblasts (IPF). We thus wanted to investigate involved genes and pathways by microarray analysis. We treated normal human lung fibroblasts with Azithromycin (50uM) for 24h and compared them to non-treated samples.

2019-11-07 | E-MTAB-8488 | biostudies-arrayexpress

Transcription profiling of human airway epithelium treated with azithromycin and SMM

Project description:Microarrays were used to evaluate the effects of azithromycin and an inflammatory stimulus (SMM) on human airway epithelium. Effects of azithromycin treatment were evaluated at 6, 24 and 48 hours. Effects of SMM were evaluated at 6 and 24 hours. In addition, pretreatment with azithromycin was used to evaluate the modulatory effects on SMM-induced inflammation. SMM=supernatant from microcorpulent material from human cystic fibrosis airways. Experiment Overall Design: 10 treatments total, 3-4 samples (patient codes = replicates) per treatment.

2009-05-27 | E-GEOD-10592 | biostudies-arrayexpress

Differential gene expression from azithromycin and SMM treated human airway epithelium

2009-05-19 | GSE10592 | GEO

Azithromycin treatment modifies airway and blood gene expression networks in neutrophilic COPD

Project description:Long-term, low dose azithromycin reduces exacerbation frequency in COPD yet the mechanism remains unclear. This study characterises changes to gene expression in patients with neutrophilic COPD in response to long term low dose azithromycin therapy. Patients with neutrophilic COPD (>61% or >162x10^4/mL sputum neutrophils) were randomised to 12 weeks of either azithromycin or placebo treatment. RNA was extracted from sputum and blood collected before (pre) and after (post) treatment.

2018-11-14 | GSE119314 | GEO

ribosome frofiling with or without 16 mg/L azithromycin treated in pseudomonas aeruginosa UCBPP-PA14

Project description:Azithromycin binds to the nascent peptide exit tunnel (NPET) close to the peptidyltransferase center (PTC) of the ribosome, which obstructs the NPET and subsequently induces ribosome stalling and depletion of intracellular pools of tRNAs. To understand the mechanism through which azithromycin represses the transcription of mutation promoting genes, we utilized ribosome profiling to analyze azithromycin caused redistribution of ribosomes on the cellular mRNAs. Wild type PA14 was treated with 16 mg/L azithromycin for 3 hours.

2024-01-01 | GSE245932 | GEO

Effects of azithromycin on blood inflammatory gene expression and cytokine production in sarcoidosis

Project description:The effects of azithromycin on whole blood gene expression using the nCounter XT human autoimmune profiling panel was assessed in 8 sarcoidosis patients before and after 1 month of azithromycin treatment.

2024-08-14 | GSE274707 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data